Summary
J&J and Bayer fail to improve prospects for blood clot drug after trial results.
Gilead Sciences offloads late-stage drug for myelofibrosis.
Mallinckrodt suffers huge blow as FDA rejects jaundice drug Stannsoporfin.
Members of my private investing community, Biotech Analysis Central, can follow this idea, as well as my other top picks with access to my model portfolio. Start your free trial today >>
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
J&J And Bayer Fail To Improve Prospects for Blood Clot Drug After Trial Results
News: Recently, Johnson & Johnson (JNJ) and Bayer (OTCPK:BAYRY) announced that their blood clot drug Xarelto failed to improve clinical outcome for at-risk patients with a disease known as venous thromboembolism (VTE). VTE is characterized as blood clots that occur deep in the veins in certain areas of the body. A blood clot that forms in the leg, arm, groin is characterized as deep vein thrombosis. When a blood clot occurs in the lungs, it's known as pulmonary embolism. The randomized double-blind placebo controlled trial, which was published in The New England Journal of Medicine, failed to achieve the primary efficacy outcome measure. The goal was to see if Xarelto could reduce the risk of symptomatic venous thromboembolism and death due to venous thromboembolism compared to placebo. Unfortunately, this goal was not achieved. The final p-value failed to be statistically significant for those who took Xarelto with a p-value of p = 0.14.
